US5837539A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies for human mesenchymal stem cells
Assignee: Mesoblast International SARL
•
Filing: 1995-06-02
•
Granted: 1998-11-17
•
Expires: 2015-06-02
Abstract
Abstract The invention relates to isolated human mesenchymal stem cells, a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. mesenchymal stem cells or "MSCs"), and characterization of (including by cytokine expression profiling) and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Further disclosed are monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.
Inventors
- 👤 Arnold I. Caplan
- 👤 Stephen E. Haynesworth
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 18:52
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/28; A61K; A61K35/00; A61K35/12; A61K35/28; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/3834; A61L27/3839; A61L27/3843; A61L27/3895; A61L31/00; A61L31/005; C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C12; C12N; C12N5/00; C12N5/0068; C12N5/06; C12N5/0602; C12N5/0652; C12N5/0662; C12N5/0663; A61F2/30; A61F2/30756; A61K2035/124; A61L2430/00; A61L2430/10; C12N2501/00; C12N2501/20; C12N2501/23; C12N2501/2301; C12N2501/30; C12N2501/38; C12N2501/39; C12N2533/00; C12N2533/10; C12N2533/18
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
29 words
An isolated antibody which binds to the same epitope on human mesenchymal stem cells as the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10743.
Claim 2
Dependent Claim
29 words
An isolated antibody which binds to the same epitope on human mesenchymal stem cells as the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10743.
Claim 3
Dependent Claim
23 words
The antibody of claim 1 wherein the antibody is the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10743.
Claim 4
Dependent Claim
29 words
An isolated antibody which binds to the same epitope on human mesenchymal stem cells as the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10744.
Claim 5
Dependent Claim
29 words
An isolated antibody which binds to the same epitope on human mesenchymal stem cells as the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10744.
Claim 6
Dependent Claim
23 words
The antibody of claim 3 wherein the antibody is the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10744.
Claim 7
Dependent Claim
29 words
An isolated antibody which binds to the same epitope on human mesenchymal stem cells as the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10745.
Claim 8
Dependent Claim
29 words
An isolated antibody which binds to the same epitope on human mesenchymal stem cells as the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10745.
Claim 9
Dependent Claim
23 words
The antibody of claim 5 wherein the antibody is the antibody produced by the hybridoma cell line deposited as ATCC Accession No. 10745.
Claim 10
Dependent Claim
11 words
A hybridoma cell line which produces the antibody of claim 1.
Claim 11
Dependent Claim
19 words
The hybridoma cell line of claim 7, wherein the hybridoma cell line is deposited as ATCC Accession No. 10743.
Claim 12
Dependent Claim
11 words
A hybridoma cell line which produces the antibody of claim 3.
Claim 13
Dependent Claim
19 words
The hybridoma cell line of claim 9, wherein the hybridoma cell line is deposited as ATCC Accession No. 10744.
Claim 14
Dependent Claim
11 words
A hybridoma cell line which produces the antibody of claim 5.
Claim 15
Dependent Claim
19 words
The hybridoma cell line of claim 11, wherein the hybridoma cell line is deposited as ATCC Accession No. 10745.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-11-16 | 2002-05-18 | 2002-11-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-11-16 | 2006-05-18 | 2006-11-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-11-16 | 2010-05-18 | 2010-11-17 | $7700.00 | Window Closed / Lapsed |